Chemotherapy plus radiation for early-stage NK/T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether combining chemotherapy with radiation therapy can work well for people with early-stage NK/T-cell lymphoma that started in the nose or throat. It aims to find a more effective treatment approach with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lymphoma called NK/T-cell lymphoma, confirmed by a biopsy.
- The lymphoma should be in the early stages (I or II) and located in the nose, sinuses, throat, or mouth area.
- You cannot have had any prior chemotherapy, radiation, or other cancer treatment for this lymphoma.
- You must be between 18 and 75 years old and in reasonably good health (able to care for yourself).
- Your blood counts, liver, kidney, and heart function must be within certain safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the immunotherapy drug sintilimab to a standard chemotherapy regimen (P-GEMOX) works better than chemotherapy alone for people with advanced ENKTL lymphoma. The goal is to see if the combination improves outcomes.
This trial tests a treatment plan that uses a combination of a chemotherapy drug (pegaspargase) and radiation therapy, adjusting the treatment based on how well the cancer responds. It aims to improve outcomes for people with early-stage NK/T-cell lymphoma while reducing side effects.
This study tests a new combination of medications for people with early-stage nasal natural killer/T-cell lymphoma. The goal is to see if adding a targeted therapy to standard treatment helps control the disease with manageable side effects.
This trial tests a combination of an immunotherapy drug (PD-1 antibody, which helps your immune system fight cancer) and radiation therapy for people with early-stage nasal-type NK/T-cell lymphoma. It aims to see if this approach is safe and effective as a first treatment.
This trial tests whether adding a medicine called tislelizumab to radiation works better than radiation alone for newly diagnosed nasal (nasal-type) NK/T-cell lymphoma. If you qualify, it may help control the cancer and improve outcomes by using both treatments together.
This trial studies whether adding toripalimab (an immune therapy that targets PD-1) to standard chemo-radiation works better for newly diagnosed early-stage nasal natural killer/T-cell lymphoma. It’s designed to see if the combined treatment can improve outcomes while staying safe.
Hear when a new Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.